The US Food and Drug Administration (FDA) has granted clearance to the Rapid LVO automated software, which is designed to detect suspected large-vessel occlusions (LVOs). The software may aid the triage process or help physicians make decisions about transferring patients, according to RapidAI, the company that manufactures it.
Rapid LVO "combines a vessel tracker and vessel destiny analysis to achieve a higher sensitivity and specificity than currently available techniques," Greg Albers, MD, cofounder of RapidAI, professor of neurology at Stanford University, and director of the Stanford Stroke Center, Stanford, California, told Medscape Medical News.
The software yields results in as few as 3 minutes and identifies LVOs with a sensitivity of 97% and a specificity of 96%. It notifies the stroke team immediately when it detects a suspected LVO. The software is appropriate for patients who present to the emergency department with symptoms of stroke, said Albers.
"LVOs are the most disabling and deadly ischemic strokes," Albers said in a company press release. "The ability to identify LVOs rapidly facilitates more effective treatment. This is why we are very excited about the FDA clearance of Rapid LVO, a significant step forward in stroke diagnostics and care."
Rapid LVO will be available this week.
RapidAI, headquartered in Menlo Park, California, develops imaging technology for patients with stroke. Its Rapid software platform uses artificial intelligence to create high-quality images from noncontrast CT, CT angiography, CT perfusion, and MRI diffusion and perfusion scans.
For more Medscape Neurology news, join us on Facebook and Twitter.
Cite this: FDA Clears Rapid Large-Vessel Occlusion Detection Software - Medscape - Aug 14, 2020.